It was worth noting that only 16.7% of patients in this study had acquired T790M, probably caused by preference selection of clinicians as some research data suggested that negative T790M may be a favorable factor for immunotherapy in NSCLC patients who failed EGFR-TKI treatment [21]. Here, EGFR is linked to non-small cell lung carcinoma.